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 During the past decade, podocytes have 
emerged as the culprit in the vast majority 
of proteinuric kidney diseases. 1 Th e inter-
digitating foot processes (FPs) of neighbor-
ing podocytes are connected by porous slit 
diaphragms and hence form sieve-like 
structures that prevent the loss of plasma 
proteins into the urine. Th e majority of 
proteinuric kidney diseases share as an 
ultrastructural hallmark the loss of the 
interdigitating podocyte FP structure, a 
process called FP eff acement. It is generally 
accepted that FP eff acement represents the 
cause of proteinuria in most cases of 
glomerular proteinuria. Th e view of the 
podocytic fi lter barrier has changed from 
static to highly dynamic with podocyte FPs 
that can rapidly reorganize their actin-
based cytoskeleton and change their struc-
ture and function: in the classical 
experimental perfusion of rat kidneys with 
the polycation protamine sulfate, FP eff ace-
ment develops within a few minutes and 
can be fully reversed within minutes of per-
fusion with the polyanion heparin. 2 Th ese 
rapid changes of podocyte FP architecture 
require that FPs are able to retract or elon-
gate, hence move, quickly along the 
glomerular basement membrane. Reiser 
and colleagues extended this observation 
using cultured podocytes to study their 
motility patterns. 3 Indeed, stimuli that lead 
to the development of FP effacement 
 in vivo (for example, lipopolysaccharide or 
puromycin aminonucleoside) commonly 
cause hypermotility of cultured podocytes 
in cell migration assays. 1,3 Based on these 
observations, the term  ‘ podocyte motility ’ 
has been coined, referring to dynamic reor-
ganization of the interdigitating FP struc-
ture  in vivo , and to the cell migration of 
cultured podocytes  in vitro that is seen as 
surrogate for the former. Current belief is 
that a stationary podocyte phenotype 
refl ects a stable FP structure with intact slit 
diaphragms, whereas hypermotility would 
manifest as FP eff acement  in vivo . 1 
 Supposing that the reorganization of 
podocyte FP structure refl ects a form of 
cell motility, it is reasonable to assume 
that the cellular pathways involved are 
similar to those involved in cell migra-
tion, for instance, of tumor cells, one of 
the most intensively studied forms of cell 
migration. 4 The Rho family of small 
GTPases — RhoA, Rac1, and Cdc42 — are 
key players in the regulation of actin 
dynamics and cell migration. 4 In the tradi-
tional view, Rac1 and Cdc42 promote cell 
motility at the leading edge through the 
formation of lamellipodia and fi lopodia, 
respectively. On the contrary, RhoA pro-
motes the formation of contractile actin- 
and myosin-containing stress fi bers in the 
cell body and at the rear of the migrating 
cell. Th is simplistic idea, though, has been 
recently challenged by the fi nding that all 
three GTPases are activated at the leading 
edge of migrating cells in a highly spatio-
temporally coordinated manner. 5 
 Several studies have suggested an 
involvement of the small GTPases RhoA, 
Rac1, and Cdc42 in podocytes during 
glomerular disease (all reviewed by Mun-
del and Reiser 1 ). Induction of the podo-
cyte urokinase plasminogen activator 
receptor (uPAR) or of its circulating form 
suPAR 6 leads to increased podocyte 
motility  in vitro and FP eff acement and 
proteinuria  in vivo through activation of 
podocyte   3 -integrin, which in turn pro-
motes Cdc42 and Rac1 signaling. Fur-
thermore, the podocyte adaptor protein 
synaptopodin has been shown to induce 
stress fi bers by stabilizing RhoA and sup-
presses fi lopodia by disrupting Cdc42 –
 IRSp53 – Mena signaling complexes. Th e 
Mena inhibitor FP(4)-Mito suppresses 
aberrant fi lopodia formation in cultured 
synaptopodin knock-down podocytes 
and protects against lipopolysaccharide-
induced proteinuria in mice  in vivo . Th ese 
data, together with the observations that 
(1) many proteinuric stimuli that lead to 
FP eff acement  in vivo induce a loss of 
actin stress fi bers in cultured podocytes, 
(2) overexpression of RhoA induces the 
formation of stress fi bers in many cell 
types, and (3) RhoA and Rac1 / Cdc42 
antagonistically regulate each other, sug-
gested the following concept: RhoA sta-
bilizes the podocyte FP structure and 
protects from eff acement and proteinuria, 
whereas Rac1 and Cdc42 promote FP 
motility and promote the development of 
FP eff acement and proteinuria. 1 
 A number of novel  in vivo observations 
are now further developing this model of 
podocyte FP dynamics. Whereas podo-
cyte-specifi c ablation of Rac1 protected 
mice from protamine sulfate-induced FP 
eff acement as expected from the above, 
ablation of Cdc42 did not protect the 
fi lter barrier yet led to proteinuria. 7 Hence, 
these findings point toward divergent 
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functions of Rac1 and Cdc42. Further-
more, inhibition of Rho-kinase, a down-
stream effector of RhoA, ameliorated 
proteinuria in several models of protein-
uria (reviewed by Zhu  et al. 8 ). Most 
recently, Zhu  et al. 8 have shown that 
inducible overexpression of a constitutive 
active variant of RhoA (CA-RhoA) in 
mice caused podocyte FP eff acement and 
proteinuria. Taken together, these data 
indicated that although basal levels of 
RhoA may be necessary to maintain podo-
cyte FP structure, overactivation of RhoA 
in disease seems to be also detrimental 
to podocytes, and the cellular response is 
FP eff acement. 
 Wang  et al. 9 (this issue) confirm the 
fi ndings of Zhu  et al. 8 (that overexpression 
of CA-RhoA causes proteinuria) and 
extend them in an important way, show-
ing that overexpression of dominant-
negative RhoA (DN-RhoA) also leads to 
podocyte FP eff acement and proteinuria. 
Importantly, although, as expected, the 
downstream pathways that were altered in 
the two transgenic mouse models diff ered, 
both mouse lines exhibited a remarkable 
similarity at the ultrastructural level; that 
is, both podocyte-specifi c overactivation 
and inactivation of RhoA lead to podocyte 
FP eff acement. 
 What do we learn from these studies? 
First, the study by Wang  et al. 9 shows that 
both too much and too little podocyte FP 
motility may be detrimental to glomerular 
health ( Figure 1 ). Although the motility of 
podocytes overexpressing CA- or DN-
RhoA has not been directly assessed in this 
study, a recent study has shown that DN-
RhoA induced, whereas CA-RhoA abro-
gated, motility of cultured podocytes. 10 
Hence, some basal podocyte motility may 
be required to maintain a functioning 
glomerular filtration barrier, whereas 
hypermotility may disrupt the podocyte 
slit diaphragm structure and promote FP 
eff acement. Podocyte health thus requires 
a healthy balance between the two 
extremes. Second, and more importantly, 
the study by Wang  et al. 9 demonstrates 
that too much and too little podocyte 
motility both result in podocyte FP eff ace-
ment. Both the podocyte FP morphology 
and the time course over which proteinu-
ria developed were remarkably similar 
between the two mouse strains overex-
pressing either CA- or DN-RhoA. 9 Th us, 
continuous FP motility may be required to 
maintain the interdigitating FP structure, 
with  hypermotility leading as quickly and 
directly to FP eff acement as hypomotility. 
This differs from the idea of too much 
RhoA activity causing chronic damage to, 
and ultimately detachment of, podocytes 
due to their failure to adapt to changes in 
their environment. More gene rally speak-
ing, the study supports the hypothesis that 
podocyte FP eff acement is the fi rst, and 
probably a universal, morphological sign 
of podocyte injury. Th ird, the study ques-
tions the simplifi ed analogy that promi-
nent stress fi bers in cultured podocytes 
refl ect intact FPs  in vivo , whereas the loss 
of actin stress fi bers and reorganization 
into cortical actin  in vitro equals FP eff ace-
ment  in vivo . As expected, expression of 
CA-RhoA in cultured podocytes induced 
more actin stress fi bers, whereas expres-
sion of DN-RhoA abrogated stress fi bers. 9 
However, since both morpho logical phe-
notypes of cultured podocytes translated 
into proteinuria and FP eff acement  in vivo , 
we may in the future have to more criti-
cally assess  in vitro podocyte structure 
upon treatment with drugs or genetic 
manipulation, as an increase in actin stress 
fi bers may be as much a sign of podocyte 
damage as a loss of stress fi bers. 
 All the above being said about podocyte 
motility and its infl uence on FP structure 
 in vivo , one needs to keep in mind a caveat: 
in light of recent fi ndings that RhoA as well 
as Rac1 and Cdc42 are active at the leading 
edge of migrating cells, although in a highly 
coordinated and mutually antagonistic 
way, 5 we need to be prepared to once again 
redefi ne the current view that RhoA activ-
ity equals a stationary podocyte phenotype 
and Rac1 / Cdc42 a motile phenotype (see 
above). Although CA-RhoA and DN-Rac1 
inhibited podocyte motility whereas DN-
RhoA and CA-Rac1 increased podocyte 
motility  in vitro , 10 these fi ndings may not 
readily translate into the  in vivo situation 
of podocyte FPs on the glomerular base-
ment membrane. It seems more probable 
that all three small Rho-family GTPases 
are active at the tip of the extending or 
retracting FPs in a highly coordinated 
manner, as shown for cultured mouse 
embryonic fi broblasts. 5 Furthermore, all 
three small Rho-family GTPases have been 
implicated in a broad variety of cellular 
processes other than cell motility, includ-
ing adhesion, proliferation, and apoptosis. 4 
Further studies will be required to unravel 
the detailed downstream signaling cas-
cades of the small GTPases in podocytes 
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 Figure 1  |  Schematic illustration outlining the tuning of podocyte foot process structure 
and function by Rho GTPases. Both too much and too little RhoA activity causes podocyte 
foot process (FP) effacement and proteinuria. The overall dynamic operation of podocyte FPs is 
regulated by an interplay of Rho GTPase family members and associated proteins such as RhoA-
activated Rac1 GTPase-activating protein (Arhgap24) as well as the large GTPase dynamin. FP 
effacement might be reversible, yet failure to restore balance of GTPase signaling will eventually 
lead to loss of podocytes and progression of glomerular disease. ESRD, end-stage renal disease. 
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 Although modest and progressive improve-
ments have been made, survival rates of 
conventionally treated hemodialysis 
and the exact mechanisms leading to FP 
eff acement and proteinuria in RhoA over- 
and underactivity, as well as how they 
functionally interact with the large GTPase 
dynamin that is heavily expressed in podo-
cyte FPs to also regulate F-actin organiza-
tion and fi lter operation. 1 
 Given the complexity of the functional 
role of small GTPases in podocyte FPs, the 
study by Wang  et al. 9 puts forward valuable 
novel  in vivo information for a  fascinating 
and expanding topic in glomerular biology: 
the tuning of kidney filter function by 
means of podocyte dynamics. 
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 Alternate-day dialysis may be 
needed for hemodialysis patients 
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 Zhang  et al. studied the relationship between day of the week and all-
cause and cardiovascular mortality in the United States, Europe, and 
Japan. The study confirms findings of studies of US patients that risk of 
all-cause and cardiac mortality is higher after a long interdialytic 
interval, and shows that this is also true in Europe and Japan. Alternate-
day dialysis may improve patient survival on hemodialysis, but 
randomized trials are necessary to establish a new schedule. 
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patients remain disappointing. 1 As has 
long been the case, most hemodialysis 
patients worldwide continue to receive 
maintenance treatment three times a week, 
with a 2 – day interval at weekends, a stand-
ard of practice that lacks the solid founda-
tion of randomized trial. To an external 
observer (armed with the knowledge that 
overt cardiovascular disease is typically 
present and uremia, in and of itself, limits 
the ability to deal with hypervolemia, 
hypovolemia, and hyperkalemia), the fact 
that standard practice mandates a 2-day 
interval between treatments might be 
counterintuitive. 
 Hemodialysis three times per week 
gives patients a 2-day interdialytic interval 
from Friday to Monday or from Saturday 
to Tuesday. Bleyer  et al. , 2 using United 
States Renal Data System data from the 
1990s, showed that all hemodialysis 
patients experienced higher risk of sud-
den and cardiac death on Monday and 
Tuesday — whether schedules were 
Monday – Wednesday – Friday (MWF) or 
Tuesday – Th ursday – Saturday (TTS) was 
unknown — and showed similar fi ndings 
in a well-characterized subset whose 
schedules were known, with the highest 
mortality rates on Mondays for MWF and 
Tuesdays for TTS patients. It is reasonable 
to assume that risk was higher on Mon-
days for patients on an MWF schedule 
and on Tuesdays for patients on a TTS 
schedule. Non-cardiac death was more 
evenly distributed in hemodialysis 
patients. In contrast, sudden death and 
cardiac death were more evenly distrib-
uted among peritoneal dialysis patients. 
Foley  et al. 3 recently confi rmed these fi nd-
ings in more contemporary US hemodi-
alysis patients, with a clearly higher risk of 
all-cause mortality and cause-specific 
mortality (cardiac, infectious, cardiac 
arrest, and myocardial infarction) and 
higher risk of myocardial infarction, con-
gestive heart failure, stroke, and dysrhyth-
mia hospitalizations on the day aft er the 
long interdialytic interval. 
 Zhang  et al. 4 (this issue), using data 
from the Dialysis Outcomes and Practice 
Patterns Study (DOPPS), confirm the 
fi ndings of previous studies in US hemo-
dialysis patients and, importantly, extend 
the observations to European and 
Japanese hemodialysis patients. As comor-
bidity, catheter use, and likelihood of skip-
ping dialysis sessions are higher in the 
United States than in Europe or Japan, and 
dialysis times are shorter, fi ndings from 
the DOPPS suggest that the fi ndings from 
the previous studies are not confi ned to 
the United States and are not completely 
explained by the burden of comorbidity, 
catheter use, missed treatments, and 
shorter dialysis times. 
 The study by Zhang and colleagues 4 
shows additional mortality patterns not 
